We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JBIO
126
Jade Biosciences
JBIO
$1.16B
$6.32M 0.08%
15,306
– –
NTLA icon
127
Intellia Therapeutics
NTLA
$1.49B
$6.29M 0.08%
53,200
– –
SYRS
128
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.99M 0.08%
183,750
– –
TARA icon
129
Protara Therapeutics
TARA
$218M
$5.61M 0.07%
830,641
+380,641
+85% +$2.62M
NRIX icon
130
Nurix Therapeutics
NRIX
$2.46B
$5.34M 0.07%
184,468
-394,115
-68% -$11.9M
SRPT icon
131
Sarepta Therapeutics
SRPT
$1.62B
$5.29M 0.07%
58,700
-6,000
-9% -$513K
NBP
132
NovaBridge Biosciences American Depositary Shares
NBP
$192M
$5.27M 0.07%
111,120
– –
OBIO icon
133
Orchestra BioMed
OBIO
$234M
$5.04M 0.06%
500,000
– –
IPSC icon
134
Century Therapeutics
IPSC
$373M
$4.87M 0.06%
307,047
-100,000
-25% -$1.88M
PHGE icon
135
BiomX
PHGE
$1.96M
$4.5M 0.06%
14,808
– –
ALXO icon
136
ALX Oncology
ALXO
$261M
$4.46M 0.06%
207,600
+57,600
+38% +$2.48M
IFRX icon
137
InflaRx
IFRX
$246M
$4.17M 0.05%
875,297
-188,821
-18% -$759K
TRML
138
DELISTED
Tourmaline Bio
TRML
$3.78M 0.05%
24,724
– –
REUN
139
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$3.72M 0.05%
307,694
– –
INZY
140
DELISTED
Inozyme Pharma
INZY
$3.59M 0.05%
526,600
+232,600
+79% +$2.01M
SGHT icon
141
Sight Sciences
SGHT
$290M
$3.51M 0.05%
200,000
– –
XFOR icon
142
X4 Pharmaceuticals
XFOR
$375M
$3.15M 0.04%
45,795
– –
WHWK
143
Whitehawk Therapeutics
WHWK
$182M
$3.08M 0.04%
127,600
-218,662
-63% -$5.49M
EXAI
144
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$2.47M 0.03%
+125,000
New +$2.63M
SURF
145
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.24M 0.03%
467,945
-441,721
-49% -$2.85M
ASLN
146
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.21M 0.03%
49,250
– –
DRUG
147
Bright Minds Biosciences
DRUG
$685M
$2.13M 0.03%
+132,120
New +$2.94M
ADAG
148
Adagene
ADAG
$252M
$2.12M 0.03%
263,176
-11,824
-4% -$121K
APTX
149
DELISTED
Aptinyx Inc. Common Stock
APTX
$2M 0.03%
749,500
+596,215
+389% +$1.43M
GYRE icon
150
Gyre Therapeutics
GYRE
$639M
$1.58M 0.02%
230,587
-130,960
-36% -$2.24M
4 5
6
7 8

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.